These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Diabodies: molecular engineering and therapeutic applications. Wu C Drug News Perspect; 2009 Oct; 22(8):453-8. PubMed ID: 20016854 [TBL] [Abstract][Full Text] [Related]
5. Structural understanding of stabilization patterns in engineered bispecific Ig-like antibody molecules. Jordan JL; Arndt JW; Hanf K; Li G; Hall J; Demarest S; Huang F; Wu X; Miller B; Glaser S; Fernandez EJ; Wang D; Lugovskoy A Proteins; 2009 Dec; 77(4):832-41. PubMed ID: 19626705 [TBL] [Abstract][Full Text] [Related]
6. Application of the Fc fusion format to generate tag-free bi-specific diabodies. Asano R; Ikoma K; Kawaguchi H; Ishiyama Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I FEBS J; 2010 Jan; 277(2):477-87. PubMed ID: 20015073 [TBL] [Abstract][Full Text] [Related]
7. Bifunctional antibody-Renilla luciferase fusion protein for in vivo optical detection of tumors. Venisnik KM; Olafsen T; Loening AM; Iyer M; Gambhir SS; Wu AM Protein Eng Des Sel; 2006 Oct; 19(10):453-60. PubMed ID: 16882674 [TBL] [Abstract][Full Text] [Related]
8. Current perspectives of bispecific antibody-based immunotherapy. Talac R; Nelson H J Biol Regul Homeost Agents; 2000; 14(3):175-81. PubMed ID: 11037049 [TBL] [Abstract][Full Text] [Related]
9. Rational and "irrational" design of proteins and their use in biotechnology. Nixon AE; Firestine SM IUBMB Life; 2000 Mar; 49(3):181-7. PubMed ID: 10868908 [TBL] [Abstract][Full Text] [Related]
10. Immunotherapy with bispecific antibodies. Thielemans KM Verh K Acad Geneeskd Belg; 1995; 57(3):229-47; discussion 247-8. PubMed ID: 7483816 [TBL] [Abstract][Full Text] [Related]
11. The rapid discovery of engineered antibodies. Wang M; He M IDrugs; 2007 Aug; 10(8):562-5. PubMed ID: 17665332 [TBL] [Abstract][Full Text] [Related]
12. Engineered systems for detection and discovery of nuclear hormone-like compounds. Gillies AR; Skretas G; Wood DW Biotechnol Prog; 2008; 24(1):8-16. PubMed ID: 18081307 [TBL] [Abstract][Full Text] [Related]
13. Recombinant bispecific antibodies for cancer therapy. Kontermann RE Acta Pharmacol Sin; 2005 Jan; 26(1):1-9. PubMed ID: 15659107 [TBL] [Abstract][Full Text] [Related]
14. Antibody therapeutics, antibody engineering, and the merits of protein stability. Demarest SJ; Glaser SM Curr Opin Drug Discov Devel; 2008 Sep; 11(5):675-87. PubMed ID: 18729019 [TBL] [Abstract][Full Text] [Related]
15. Alternative non-antibody scaffolds for molecular recognition. Skerra A Curr Opin Biotechnol; 2007 Aug; 18(4):295-304. PubMed ID: 17643280 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic antibody production technologies: molecules, applications, expression and purification. Humphreys DP; Glover DJ Curr Opin Drug Discov Devel; 2001 Mar; 4(2):172-85. PubMed ID: 11378956 [TBL] [Abstract][Full Text] [Related]
17. Downstream processing of value-added proteins in biotechnology: An Indian scenario. Babu AK; Vijayalakshmi MA Biotechnol J; 2009 Aug; 4(8):1132-9. PubMed ID: 19360713 [No Abstract] [Full Text] [Related]